Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 9/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | KHK | P50053 | 1/20 | 0.47 |
| ▸ | TRIM58 | Q8NG06 | 2/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL3590620 | 0.98 | GBA1 (0.52) | GBA1KDM1AMAOBMAOACARM1 | |
| Hydrochloric Acid SCHEMBL28223443 | 0.98 | GBA1 (0.52) | GBA1KDM1AMAOBMAOACARM1 | |
| SCHEMBL1203475 | 0.89 | KDM1A (0.55) | GBA1KDM1AMAOBMAOACARM1 | |
| SCHEMBL27551537 | 0.89 | KDM1A (0.55) | GBA1KDM1AMAOBMAOACARM1 | |
| SCHEMBL18434523 | 0.86 | CARM1 (0.57) | GBA1CARM1PRMT6SIGMAR1NPC1 | |
| SCHEMBL10055002 | 0.86 | CARM1 (0.57) | GBA1CARM1PRMT6SIGMAR1NPC1 | |
| SCHEMBL10055063 | 0.86 | CARM1 (0.57) | GBA1CARM1PRMT6SIGMAR1NPC1 | |
| SCHEMBL1722281 | 0.86 | CARM1 (0.57) | GBA1CARM1PRMT6SIGMAR1NPC1 | |
| SCHEMBL872221 | 0.82 | CARM1 (0.54) | GBA1CARM1PRMT6NPC1RAB9A | |
| SCHEMBL9679337 | 0.82 | EPHX1 (0.54) | CARM1PRMT6NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464245-B1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-10370338-B2 | Benzazepine dicarboxamide compounds with tertiary amide function | HOFFMANN-LA ROCHE INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3464245-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-20190077763-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | HOFFMANN-LA ROCHE INC. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-2231680-B1 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2231680-B1 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2017202704-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| US-7858784-B2 | Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858784-B2 | Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858784-B2 | Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009076622-A2 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | GBA1 1251/4885KDM1A 828/4885MAOB 319/4885 |
| US-10370338-B2 | Benzazepine dicarboxamide compounds with tertiary amide function | TLR1, TLR5, TLR4 | GBA1 1097/4885KDM1A 395/4885MAOB 3232/4885 |
| US-20190077763-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | TLR1, TLR5, TLR4 | GBA1 1097/4885KDM1A 395/4885MAOB 3232/4885 |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | SOD1, TIMCC, TST | GBA1 3309/4885KDM1A 4416/4885MAOB 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.